A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Pradaxa (Dabigatran Etexilate Mesilate, 110 mg or 150 mg b.i.d.) in Korean Patients With Non-valvular Atrial Fibrillation(SPARK: Safety Study of Pradaxa in AF Patients by Regulatory Requirement of Korea)

Trial Profile

A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Pradaxa (Dabigatran Etexilate Mesilate, 110 mg or 150 mg b.i.d.) in Korean Patients With Non-valvular Atrial Fibrillation(SPARK: Safety Study of Pradaxa in AF Patients by Regulatory Requirement of Korea)

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Dabigatran etexilate (Primary)
  • Indications Atrial fibrillation; Embolism and thrombosis
  • Focus Adverse reactions
  • Acronyms SPARK
  • Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 27 Jun 2017 Status changed from recruiting to completed.
    • 28 Apr 2017 Planned End Date changed from 1 Feb 2017 to 17 May 2017.
    • 28 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 17 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top